Tag: Human Papillomavirus (HPV)
Positive HPV Status Tied to Better Cervical Cancer Prognosis
Five-year relative survival ratio better for hrHPV-positive cases than for hrHPV-negative cases
FDA Approves HPV Vaccine for People Through Age 45
Updated vaccine designed to prevent cancers and disease caused by nine HPV types
More Than 14 Million Preteens Need to Receive HPV Vaccine
>14 million need to receive two doses of vaccine to reach goal of 80 percent vaccination by 2026
Second HPV-Related Primary Cancers Common in Survivors
Persistent HPV infection may be associated with second HPV-related primary cancers
Total of 43,371 New Cases of HPV-Associated Cancers in 2015
Decreases in cervical cancer, vaginal SCC from 1999 to 2015; increases in oropharyngeal, anal, vulvar SCC
Oral High-Risk HPV Prevalence Appears to Be Low in England
Smoking and sexual behavior associated with high-risk HPV status
Catch-Up HPV Doses Effective to Age 21 Against Cervical Neoplasia
But catch-up doses not effective against CIN for women who initiated vaccination at 21 to 26 years
USPSTF Updates Guidance for Cervical Cancer Screening
Cytology recommended every three years from age 21; different screening options from age 30 to 65
HPV Legislation Doesn’t Impact Teen Sexual Behaviors
No substantive or significant associations between HPV legislation and adolescent sexual behaviors
No Higher Risk of Autoimmune Disorders After HPV4 Vaccination
Girls 12 to 17 have no increased risk of autoimmune disorders seven to 60 days after vaccination
